Kiadis Pharma is a clinical stage biopharmaceutical company pioneering a proprietary cell-based, personalized therapy for patients with blood cancers and related disorders, an area of significant unmet medical need.

Kiadis Pharma’s unique and powerful platform technology has led to an initial experimental product, ATIR™, which has already been clinically tested on sixty patients.

All of Kiadis Pharma’s products are based on hematopoietic (blood-forming) stem cell transplant. Each product is specific to the patient and offers a potentially significant improvement on standard of care. ATIR™ has the opportunity to expand the donor pool and improve outcomes for patients for whom matched sibling transplants are not available.

Kiadis Pharma’s mission is to become a leading provider of improved, personalized therapies to all transplant patients including those who receive hematopoietic (blood-forming) stem cell transplants from autologous (self) and allogeneic (non-self) donors including cord blood stem cell and haploidentical transplants.

At the moment, Kiadis’ therapies are experimental in nature and are not yet commercially available. The company is collaborating with more than a dozen clinical centers in Europe, Canada and the United States in a pivotal trial that is projected to complete enrollment in 2011.

Kiadis Pharma is based in Amsterdam, The Netherlands.